Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma
Ming-Fang Cheng
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Division of Histological and Clinical Pathology, Hualien Armed Forced General Hospital, Hualien, Taiwan
Both authors contributed equally to this work.Search for more papers by this authorMao-Suan Huang
Department of Dentistry, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan
Both authors contributed equally to this work.Search for more papers by this authorChun-Shu Lin
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Search for more papers by this authorLi-Han Lin
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorHerng-Sheng Lee
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Search for more papers by this authorJhih-Cheng Jiang
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Kan-Tai Hsia
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Address for correspondence: K-T Hsia, DDS, PhD, Institute of Oral Biology, School of Dentistry, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Pei-Tou, Taipei 11221, Taiwan. e-mail: [email protected]Search for more papers by this authorMing-Fang Cheng
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Division of Histological and Clinical Pathology, Hualien Armed Forced General Hospital, Hualien, Taiwan
Both authors contributed equally to this work.Search for more papers by this authorMao-Suan Huang
Department of Dentistry, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan
Both authors contributed equally to this work.Search for more papers by this authorChun-Shu Lin
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Search for more papers by this authorLi-Han Lin
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorHerng-Sheng Lee
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Search for more papers by this authorJhih-Cheng Jiang
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Kan-Tai Hsia
Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
Address for correspondence: K-T Hsia, DDS, PhD, Institute of Oral Biology, School of Dentistry, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Pei-Tou, Taipei 11221, Taiwan. e-mail: [email protected]Search for more papers by this authorAbstract
Aims
To investigate the relationship of matriptase expression in oral squamous cell carcinoma (OSCC) to clinicopathological characteristics, patient survival and cell-invasive properties.
Methods and results
Matriptase expression in OSCC was evaluated by immunohistochemical staining, and its relationship to clinicopathological features and outcomes was assessed statistically. The shRNA-mediated stable knockdown of matriptase in OSCC cells was used to analyse cell proliferation, migration and invasion in vitro. Matriptase immunostaining score was correlated with histopathological grade, clinical stage, positive lymph node and distant metastasis, and higher matriptase immunostaining score was associated significantly with poor prognosis. Elevated matriptase expression in oral cancer cell lines was a significant promoter of oral cancer cell migration and invasion.
Conclusions
Matriptase expression correlates with tumour progression and invasive capability in OSCC and may be an adverse prognostic marker for this cancer.
Supporting Information
| Filename | Description |
|---|---|
| his12361-sup-0001-TableS1.docWord document, 30.5 KB | Table S1. Relationship between matriptase intensity and distribution in 104 patients. |
| his12361-sup-0002-TableS2.docWord document, 81 KB | Table S2. Relationship between matriptase intensity and clinicopathological parameters in 104 patients. |
| his12361-sup-0003-TableS3.docWord document, 77 KB | Table S3. Relationship between matriptase distribution and clinicopathological parameterss in 104 patients. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. Oral Oncol. 2010; 46; 414–417.
- 2Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009; 15; 388–399.
- 3Haddad RI, Shin DM. Recent advances in head and neck cancer. N. Engl. J. Med. 2008; 359; 1143–1154.
- 4Howard JD, Lu B, Chung CH. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol. 2012; 48; 10–17.
- 5Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am. J. Pathol. 2002; 161; 1051–1060.
- 6Liu SY, Lu CL, Chiou CT et al. Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in taiwan. Oral Oncol. 2010; 46; 276–282.
- 7Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45; 309–316.
- 8Chen YJ, Chang JT, Liao CT et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008; 99; 1507–1514.
- 9Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 2008; 87; 14–32.
- 10da Silva SD, Ferlito A, Takes RP et al. Advances and applications of oral cancer basic research. Oral Oncol. 2011; 47; 783–791.
- 11Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol. 2012; 48; 578–584.
- 12Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cdna for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 1999; 274; 18231–18236.
- 13List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol. Med. 2006; 12; 1–7.
- 14Uhland K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci. 2006; 63; 2968–2978.
- 15Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu. Rev. Cell Dev. Biol. 2011; 27; 213–235.
- 16Lee SL, Huang PY, Roller P, Cho EG, Park D, Dickson RB. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation. Mech. Dev. 2010; 127; 82–95.
- 17Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 2000; 275; 36720–36725.
- 18Qiu D, Owen K, Gray K, Bass R, Ellis V. Roles and regulation of membrane-associated serine proteases. Biochem. Soc. Trans. 2007; 35; 583–587.
- 19Lee MS, Tseng IC, Wang Y et al. Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am. J. Physiol. Cell Physiol. 2007; 293; C95–C105.
- 20Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 1999; 274; 18237–18242.
- 21Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J. Biol. Chem. 2003; 278; 26773–26779.
- 22List K, Haudenschild CC, Szabo R et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21; 3765–3779.
- 23List K, Currie B, Scharschmidt TC et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J. Biol. Chem. 2007; 282; 36714–36723.
- 24Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009; 69; 1828–1835.
- 25Lee JW, Yong Sonzrg S, Choi JJ et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol. 2005; 36; 626–633.
- 26Tanimoto H, Shigemasa K, Tian X et al. Transmembrane serine protease TADG-15 (ST14/matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br. J. Cancer 2005; 92; 278–283.
- 27Kosa P, Szabo R, Molinolo AA, Bugge TH. Suppression of tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene 2012; 31; 3679–3695.
- 28Najy AJ, Won JJ, Movilla LS, Kim HR. Differential tumorigenic potential and matriptase activation between PDGF b versus PDGF d in prostate cancer. Mol. Cancer Res. 2012; 10; 1087–1097.
- 29Miller GS, List K. The matriptase–prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res. 2013; 351; 245–253.
- 30 SB Edge, DR Byrd, CC Compton, AG Fritz, FL Greene, A Trotti eds. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
- 31Cheng MF, Tzao C, Tsai WC et al. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis. Esophagus 2006; 19; 482–486.
- 32Meng CL, Yang CY, Shen KL, Wong PY, Lee HK. Inhibition of the synthesis of eicosanoid-like substances in a human oral cancer cell line by interferon-gamma and eicosapentaenoic acid. Arch. Oral Biol. 1998; 43; 979–986.
- 33Hung RJ, Hsu Ia W, Dreiling JL et al. Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell–cell contacts. Am. J. Physiol. Cell Physiol. 2004; 286; C1159–C1169.
- 34Chen SF, Chang YC, Nieh S, Liu CL, Yang CY, Lin YS. Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS ONE 2012; 7; e31864.
- 35List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am. J. Pathol. 2006; 168; 1513–1525.
- 36List K, Szabo R, Molinolo A et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 2005; 19; 1934–1950.
- 37Jin JS, Cheng TF, Tsai WC, Sheu LF, Chiang H, Yu CP. Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol. Histopathol. 2007; 22; 305–309.
- 38Kang JY, Dolled-Filhart M, Ocal IT et al. Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003; 63; 1101–1105.
- 39Tsai WC, Chu CH, Yu CP et al. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis. Markers 2008; 24; 89–99.
- 40Nakamura K, Hongo A, Kodama J et al. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res. 2009; 29; 1685–1690.
- 41Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 2006; 49; 388–395.
- 42Susuki D, Kimura S, Naganuma S et al. Regulation of microrna expression by hepatocyte growth factor in human head and neck squamous cell carcinoma. Cancer Sci. 2011; 102; 2164–2171.
- 43Szabo R, Rasmussen AL, Moyer AB et al. C-met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 2011; 30; 2003–2016.
- 44Baba T, Kawaguchi M, Fukushima T et al. Loss of membrane-bound serine protease inhibitor hai-1 induces oral squamous cell carcinoma cells' invasiveness. J. Pathol. 2012; 228; 181–192.
- 45Angadi PV, Savitha JK, Rao SS, Sivaranjini Y. Oral field cancerization: current evidence and future perspectives. Oral Maxillofac. Surg. 2012; 16; 171–180.
- 46Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin. Cancer Biol. 2005; 15; 113–120.
- 47Roesch-Ely M, Leipold A, Nees M et al. Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J. Pathol. 2010; 221; 462–470.
- 48Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral cancer: current evidence and clinical implications. J. Oral Pathol. Med. 2004; 33; 317–322.
- 49Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007; 43; 523–534.
- 50Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat. Rev. Cancer 2005; 5; 127–135.
Citing Literature
